Physician profile
Jalpa Patel
NPI 1740695428
$5,421.33
in general payments reported to CMS, 2019-2025
46 companies · $986 in 2025
The $986 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $633 · 2021: $673 · 2022: $965 · 2023: $853 · 2024: $794 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,525 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,525.27 |
| Education | $108.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $720.75 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $708.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $537.06 | 2019-2025 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $371.19 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $285.48 | 2024-2025 | |
| Abbott Laboratories | $282.20 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $271.57 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $176.29 | 2019-2021 | |
| Pfizer INC. | $176.14 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $172.25 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $169.73 | 2019-2023 | Verquvo, Belsomra |
| Corcept Therapeutics | $142.22 | 2025 | Korlym |
| Astellas Pharma US INC | $121.66 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $97.21 | 2019-2025 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $86.66 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jalpa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.